Core Viewpoint - Kang En Bei (600572.SH) reported a slight increase in revenue and a notable rise in net profit for the first three quarters of 2025, indicating stable financial performance despite a challenging market environment [1] Financial Performance - The company achieved a revenue of 4.976 billion yuan for the first three quarters, reflecting a year-on-year growth of 1.27% [1] - The net profit attributable to shareholders reached 584 million yuan, marking a year-on-year increase of 12.65% [1] - The non-recurring net profit was reported at 431 million yuan, with a year-on-year growth of 1.61% [1] - Basic earnings per share stood at 0.232 yuan [1]

Group 1 - China Satellite reported a net profit of 14.81 million yuan for the first three quarters, marking a turnaround from losses, with a revenue of 3.102 billion yuan, up 85.28% year-on-year [1] - SAIYANG Technology signed a contract worth 533 million yuan for Airbus A320 series aircraft transport tooling, effective until 2038 [1] - Zhongwei Semiconductor achieved a net profit of 152 million yuan, a 36.78% increase year-on-year, with a revenue of 773 million yuan, up 19.03% [2] Group 2 - Jiao Cheng Ultrasonic reported a net profit of 94.03 million yuan, a significant increase of 359.81% year-on-year, with a revenue of 521 million yuan, up 27.53% [3] - Keda Li's net profit grew by 16.55% year-on-year to 1.185 billion yuan, with a revenue of 10.603 billion yuan, up 23.41% [3] - Ningbo Huaxiang's net profit fell by 87.68% to 88.73 million yuan, despite a revenue increase of 5.88% to 19.224 billion yuan [4] Group 3 - Mingzhi Electric reported a net profit of 49.84 million yuan, a 5.43% increase year-on-year, with a revenue of 2.043 billion yuan, up 11.66% [6] - Xianda Co. achieved a net profit of 196 million yuan, a staggering increase of 3064.56% year-on-year, with a revenue of 2.008 billion yuan, up 6.11% [7] - Longxin General's net profit rose by 75.45% to 1.577 billion yuan, with a revenue of 14.557 billion yuan, up 19.14% [8] Group 4 - Hainan Highway reported a net loss of 10.63 million yuan, despite a revenue increase of 133.41% to 314 million yuan [9] - Zhongci Electronics achieved a net profit of 443 million yuan, a 20.07% increase year-on-year, with a revenue of 2.143 billion yuan, up 13.62% [11] - Hangyang Co. reported a net profit of 757 million yuan, a 12.14% increase year-on-year, with a revenue of 11.428 billion yuan, up 10.39% [12] Group 5 - Yuanli Technology's net profit decreased by 2.89% to 152 million yuan, with a revenue of 1.654 billion yuan, down 3.69% [13] - Guihang Co. reported a net profit of 118 million yuan, a slight increase of 0.77%, with a revenue of 1.870 billion yuan, up 8.65% [14] - Haixing Co. achieved a net profit of 147 million yuan, a 41.41% increase year-on-year, with a revenue of 1.711 billion yuan, up 21.45% [16] Group 6 - Weiteng Electric reported a net profit decline of 87.47% to 13.66 million yuan, with a revenue of 2.597 billion yuan, down 5.40% [18] - Tiancai Control achieved a net profit of 50.33 million yuan, a 91.73% increase year-on-year, with a revenue of 1.855 billion yuan, up 27.3% [20] - Hangzhi Qianjin reported a net profit of 207 million yuan, a 9.59% increase year-on-year, with a revenue of 1.730 billion yuan, up 5.39% [21] Group 7 - Suli Co. reported a net profit of 139 million yuan, a remarkable increase of 1522.38%, with a revenue of 2.064 billion yuan, up 25.39% [23] - Sanqi Interactive achieved a net profit of 2.345 billion yuan, a 23.57% increase year-on-year, with a revenue of 12.461 billion yuan, down 6.59% [24] - Yongjie New Materials reported a net profit of 309 million yuan, a 30.99% increase year-on-year, with a revenue of 7.020 billion yuan, up 20.01% [26] Group 8 - Kang Enbei achieved a net profit of 584 million yuan, a 12.65% increase year-on-year, with a revenue of 4.976 billion yuan, up 1.27% [28] - Zhongyuan Highway reported a net profit of 961 million yuan, a 16.78% increase year-on-year, with a revenue of 4.888 billion yuan, up 3.89% [30] - Hunan Gold achieved a net profit of 1.029 billion yuan, a 54.28% increase year-on-year, with a revenue of 41.194 billion yuan, up 96.26% [32] Group 9 - Huadong Pharmaceutical reported a net profit of 2.748 billion yuan, a 7.24% increase year-on-year, with a revenue of 32.664 billion yuan, up 3.77% [33] - Dongyangguang achieved a net profit of 906 million yuan, a significant increase of 189.80%, with a revenue of 10.970 billion yuan, up 23.56% [35] - Xinrui Technology reported a net loss of 62.62 million yuan, despite a revenue increase of 28.02% to 1.672 billion yuan [37] Group 10 - Jiabiyou achieved a net profit of 129 million yuan, a 54.18% increase year-on-year, with a revenue of 428 million yuan, up 10.56% [38] - Ruifeng New Materials reported a net profit of 574 million yuan, a 14.85% increase year-on-year, with a revenue of 2.551 billion yuan, up 10.87% [39] - Zhongfu Industrial achieved a net profit of 1.187 billion yuan, a 63.25% increase year-on-year, with a revenue of 16.633 billion yuan, down 0.60% [40] Group 11 - Aohai Technology reported a net profit of 359 million yuan, a 19.32% increase year-on-year, with a revenue of 5.188 billion yuan, up 14.14% [41] - Kangzhong Medical announced a share transfer plan involving 5.33% of its shares due to shareholder funding needs [43] - Hualing Steel plans to invest 512 million yuan in a new continuous casting project [44]

Core Viewpoint - Kang En Bei (600572.SH) reported a significant increase in revenue and net profit for Q3 2025, indicating strong business performance and growth potential [1] Financial Performance - Q3 revenue reached 1.617 billion yuan, representing a year-on-year growth of 10.42% [1] - Net profit for Q3 was 230 million yuan, showing a substantial year-on-year increase of 69.11% [1] - For the first three quarters, net profit totaled 584 million yuan, reflecting a year-on-year growth of 12.65% [1] Business Drivers - The increase in net profit is primarily attributed to the growth in the company's core business performance and the rise in the market value of its holdings in Jiahe Biological at the end of the reporting period compared to the same period last year [1]

Core Viewpoint - Kang En Bei reported a significant increase in both revenue and net profit for the third quarter of 2025, indicating strong financial performance and growth potential in the market [1] Financial Performance - In Q3 2025, the company achieved a revenue of 1.617 billion yuan, representing a year-on-year growth of 10.42% [1] - The net profit attributable to shareholders for Q3 2025 was 230 million yuan, showing a substantial year-on-year increase of 69.11% [1] - For the first three quarters of 2025, the total revenue reached 4.976 billion yuan, with a modest year-on-year growth of 1.27% [1] - The net profit attributable to shareholders for the first three quarters was 584 million yuan, reflecting a year-on-year increase of 12.65% [1]

Core Viewpoint - Kang En Bei (600572.SH) announced that its wholly-owned subsidiary, Hangzhou Kang En Bei Pharmaceutical Co., Ltd., participated in the 11th batch of national centralized drug procurement, with its product adenosylcobalamin capsules expected to win the bid [1] Group 1: Company Information - Hangzhou Kang En Bei's product adenosylcobalamin capsules is selected based on market potential across various provinces [1] - The results of the bidding will be officially announced after being published by the Joint Procurement Office [1]

浙江康恩贝制药股份有限公司 董事、高级管理人员持股及变动管理办法 第一章 总则 第一条 为加强对浙江康恩贝制药股份有限公司（以下简称 "公司"）董事和高级管理人员所持本公司股份及其变动的管理， 规范公司董事和高级管理人员买卖公司股票的行为，根据《中华 人民共和国公司法》《中华人民共和国证券法》《上市公司董事 和高级管理人员所持本公司股份及其变动管理规则》《上海证券 交易所股票上市规则》《上海证券交易所上市公司自律监管指引 第8号——股份变动管理》《上海证券交易所上市公司自律监管 指引第15号——股东及董事、高级管理人员减持股份》等法律法 规、部门规章和规范性文件的相关规定，结合《浙江康恩贝制药 股份有限公司章程》（以下简称"《公司章程》"）及公司实际 情况，制定本办法。 第二条 本办法适用于公司董事和《公司章程》中确定的高 级管理人员所持本公司股份及其变动的管理。 公司董事和高级管理人员就其所持股份变动相关事项作出 承诺的，应当严格遵守。 第三条 公司董事和高级管理人员所持本公司股份，是指登 记在其名下和利用他人账户持有的所有本公司股份。公司董事和 高级管理人员开立多个证券账户的，对各证券账户的持股合并计 算 ...

为全面贯彻落实最新法律法规要求，确保公司治理与监管规定保持同步，进 一步规范公司运作机制，提升公司治理水平，根据《中华人民共和国公司法》（2023 年修订）和《上市公司章程指引》（2025 年修订）、《上海证券交易所股票上市规 则》（2025 年 4 月修订）等相关法律法规，结合公司治理实际需求，公司决定取 消监事会，原监事会的职权由董事会审计委员会承接，公司《监事会议事规则》 相应废止，公司现任监事将自公司股东大会审议通过取消监事会及修订《公司章 程》事项之日起解除职位；同时，公司拟对《公司章程》的部分条款进行修订。 1 证券简称：康恩贝 证券代码：600572 公告编号：临 2025-054 浙江康恩贝制药股份有限公司 关于修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江康恩贝制药股份有限公司(以下简称"公司")于 2025 年 10 月 27 日召 开第十一届董事会第十一次（临时）会议及第十一届监事会第九次（临时）会议， 审议通过了《关于因注销回购股份修改<公司章程>并办理工商变更登记事项的议 ...

浙江康恩贝制药股份有限公司 关联交易制度 第一章 总 则 第一条 为规范浙江康恩贝制药股份有限公司（以下简称"公 司"）及子公司的关联交易，保证关联交易的公平合理，维护公 司及中小股东的利益，根据《中华人民共和国公司法》《中华人 民共和国证券法》《上海证券交易所股票上市规则》（以下简称 "《上市规则》"）、《上海证券交易所上市公司自律监管指引 第 1 号——规范运作》《上海证券交易所上市公司自律监管指引 第 5 号——交易与关联交易》等相关法律法规、部门规章、规范 性文件及《浙江康恩贝制药股份有限公司章程》（以下简称"《公 司章程》"）的有关规定，制定本制度。 （一）直接或间接地控制本公司的法人（或者其他组织）； （二）由前项所述法人（或者其他组织）直接或间接控制的 1 除公司、公司全资或控股子公司及控制的其他主体以外的法人（或 者其他组织）； （三）公司的关联自然人直接或间接控制的、或担任董事（不 含同为双方的独立董事）、高级管理人员的，除公司、公司全资 或控股子公司及控制的其他主体以外的法人（或者其他组织）； （四）持有公司 5%以上股份的法人（或者其他组织）及其一 致行动人； （五）根据《上海证券交易所 ...

浙江康恩贝制药股份有限公司 董事会秘书管理办法 第一章 总 则 第一条 为规范董事会秘书履行工作职责，根据《中华人民 共和国公司法》(以下简称"《公司法》")、《中华人民共和国 证券法》《上海证券交易所股票上市规则》《上海证券交易所上 市公司自律监管指引第 1 号——规范运作》等法律法规以及《公 司章程》《董事会议事规则》《信息披露管理制度》规定，制定 本办法。 第二条 董事会设董事会秘书一名，为公司的高级管理人员。 第三条 董事会秘书是公司与上海证券交易所之间的指定 联络人，董事会秘书或代行董事会秘书职责的人员、证券事务代 表负责以公司名义办理信息披露、股票及其衍生品种变动管理等 事务。 第四条 董事会秘书应忠实、勤勉地履行职责并承担法律、 法规、规范性文件及《公司章程》所规定的公司高级管理人员的 义务，享有相应的工作职权。 第五条 公司设董事会秘书办公室，负责公司信息披露事务 管理，由董事会秘书分管。 (四)上海证券交易所规定的其他条件。 第六条 董事会秘书的任职资格： (一)具有良好的职业道德和个人品质； 1 (二)具备履行职责所必需的财务、管理、法律等专业知识； (三)具备履行职责所必需的工作经验； ...

浙江康恩贝制药股份有限公司 内幕信息知情人登记管理办法 第一章 总则 第一条 为加强浙江康恩贝制药股份有限公司（以下简称"公 司"）内幕信息管理，做好内幕信息保密工作，维护信息披露的 公平原则，保护广大投资者的合法权益，根据《中华人民共和国 公司法》《中华人民共和国证券法》（以下简称"《证券法》"） 《上市公司信息披露管理办法》《上海证券交易所股票上市规则》 《上市公司监管指引第 5 号——上市公司内幕信息知情人登记管 理制度》《上海证券交易所上市公司自律监管指引第 2 号——信 息披露事务管理》等法律法规、规范性文件及《公司章程》和公 司《信息披露管理制度》的有关规定，结合公司实际情况，制定 本办法。 第二条 公司董事会是内幕信息的管理机构。公司董事会应 当按照法律法规及上海证券交易所相关规则要求及时登记和报 送内幕信息知情人档案，并保证内幕信息知情人档案真实、准确 和完整，董事长为主要责任人。 董事会秘书负责组织协调公司内幕信息管理工作，并办理公 司内幕信息知情人的登记入档和报送事宜。董事长与董事会秘书 应当对内幕信息知情人档案的真实、准确和完整签署书面确认意 见。 董事会办公室为公司内幕信息知情人登记管 ...